Second-line treatment for metastatic or locally advanced gastric cancer
10.3760/cma.j.issn.0253-3766.2016.10.001
- VernacularTitle:转移性或局部晚期胃癌的二线治疗选择
- Author:
Kaichun LI
1
;
Shiyu CHENG
;
Jie DU
;
Jin LI
Author Information
1. 同济大学附属天佑医院肿瘤科
- Keywords:
Stomach neoplasms;
Neoplasm metastasis;
Drug therapy;
Second-line treatment
- From:
Chinese Journal of Oncology
2016;38(10):721-724
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer is one of the major causes of cancer?related deaths. Many patients with metastatic gastric cancer after first?line chemotherapy received salvage chemotherapy in routine clinical practice. Recent phase Ⅲ trials demonstrated substantial prolongation of overall survival to support this chemotherapy or targeted therapy as a second?line treatment. Both ramucirumab monotherapy and ramucirumab plus paclitaxel were approved by FDA in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. In addition, paclitaxel, irinotecan, or docetaxel monotherapy is also recommended for preferred regimens. This review will summarize chemotherapy or targeted therapy as a second?line treatment in advanced gastric cancer.
